Access the full text.
Sign up today, get DeepDyve free for 14 days.
E., Christiaan Hagen, Mohamed, R., Daha, JO Hermans, K. Andrassy, Elena Csernok, Gillian Gaskin, Phillippe Lesavre, J. Lüdemann, N. Rasmussen, A. Sinico, A. Wiik, Fokko, J., V. Woude (1998)
Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.Kidney international, 53 3
X. Kyndt, D. Reumaux, F. Bridoux, B. Tribout, P. Bataille, E. Hachulla, P. Hatron, P. Duthilleul, P. Vanhille (1999)
Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis.The American journal of medicine, 106 5
R. Falk, S. Hogan, T. Carey, J. Jennette (1990)
Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network.Annals of internal medicine, 113 9
J. Niles, R. McCluskey, MF Ahmad, M. Arnaout (1989)
Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase.Blood, 74 6
J. Tervaert, R. Goldschmeding, J. Elema, P. Limburg, M. Giessen, M. Huitema, M. Koolen, R. Hené, G. Hem, A. Borne, C. Kallenberg (2010)
Association of autoantibodies to myeloperoxidase with different forms of vasculitis.Arthritis and rheumatism, 33 8
J. Rao, John Feussner, Morris Weinberger, NancyB. Allen (1995)
A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosisThe Lancet, 346
Guy Hoffman, G. Kerr, R. Leavitt, C. Hallahan, R. Lebovics, W. Travis, M. Rottem, A. Fauci (1992)
Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 116
J. Tervaert, M. Huitema, W. Sluiter, T. The, G. Hem, C. Kallenberg, R. Hené (1990)
Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titreThe Lancet, 336
A. Wiik (1989)
Delineation of a standard procedure for indirect immunofluorescence detection of ANCA.APMIS. Supplementum, 6
J. Tervaert, F. Woude, A. Fauci, J. Ambrus, J. Velosa, W. Keane, S. Meijer, M. Giessen, G. Hem, C. Kallenberg (1989)
Association between active Wegener's granulomatosis and anticytoplasmic antibodies.Archives of internal medicine, 149 11
M. Cotch, G. Hoffman, Diane Yerg, G. Kaufman, Paul Targonski, R. Kaslow (1996)
The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources.Arthritis and rheumatism, 39 1
L. Guillevin, J. Cordier, Franïois Lhote, P. Cohen, B. Jarrousse, I. Royer, P. Lesavre, C. Jacquot, P. Bindi, Philippe Bielefeld, Jean-Franïois Desson, F. Détrée, A. Dubois, E. Hachulla, B. Hoen, D. Jacomy, C. Seigneuric, D. Lauque, M. Stern, M. Longy‐Boursier (1997)
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.Arthritis and rheumatism, 40 12
E. Reinhold-Keller, J. Kekow, A. Schnabel, W. Schmitt, Martin Heller, Arwed Beigel, G. Duncker, W. Gross (1994)
Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis.Arthritis and rheumatism, 37 6
A. Fauci, B. Haynes, P. Katz, S. Wolff (1983)
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.Annals of internal medicine, 98 1
W. Egner, H. Chapel (1990)
Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitidesClinical & Experimental Immunology, 82
F. Woude, S. Lobatto, H. Permin, M. Giessen, N. Rasmussen, A. Wiik, L. Es, G. Hem, T. The (1985)
AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSISThe Lancet, 325
G. Kerr, T. Fleisher, C. Hallahan, R. Leavitt, A. Fauci, G. Hoffman (1993)
Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosis.Advances in experimental medicine and biology, 336
Ulrich Specks, Christine Wheatley, Thomas McDonald, Michael Rohrbach, R. Deremee (1989)
Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis.Mayo Clinic proceedings, 64 1
AbstractObjectives. To investigate the predictive value of testing for antineutrophil cytoplasmic antibodies (ANCA) in 55 patients with systemic Wegener's granulomatosis (WG) included in a randomized, prospective trial comparing corticosteroids and oral or pulse cyclophosphamide.Methods. All 55 patients received corticosteroids. A cyclophosphamide pulse of 0.7 g/m2 was given at the time of diagnosis. After the first pulse, the patients were assigned at random to receive either pulse or oral cyclophosphamide (2 mg/kg/day), independently of ANCA results. ANCA were sought using an immunofluorescence assay and an attempt was made to correlate them with relapse of WG. ANCA were monitored throughout the study.Results. At the time of diagnosis, ANCA were detected in 48 (87%) patients, with a cytoplasmic labelling pattern in 44 and a perinuclear pattern in four. ANCA follow‐up was available for 50 patients. ANCA disappeared in 34 patients and persisted in nine. For 79% of the patients, the clinical course improved with the disappearance of ANCA and deteriorated with their persistence or increased titre. Among the patients who were initially ANCA‐positive, 23 relapses occurred. Relapses were more frequent when ANCA remained positive or reappeared [13/19 ANCA‐positive patients vs 3/29 ANCA‐negative patients (P<0.01)]. Nine relapses (39%) occurred in patients with persistent ANCA, and ANCA reappearance preceded relapse in eight (35%). The mean time between inclusion and relapse did not differ between the patients who became ANCA‐negative and those who were persistently ANCA‐positive (14.6±13.2 vs 14.4±8.2 months). The mean time to ANCA disappearance was similar for the patients who relapsed and those who did not. Corticosteroids and pulse or oral cyclophosphamide did not significantly modify the time to ANCA disappearance. Throughout the study, seven patients were ANCA‐negative.Conclusion. Although ANCA positivity was associated with relapse, discordance between cytoplasmic ANCA and disease activity was not unusual. In the absence of clinical manifestations, ANCA titres alone can serve as a warning signal but not indicate whether to adjust or initiate treatment.
Rheumatology – Oxford University Press
Published: Feb 1, 2001
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.